Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Midazolam is a short-acting benzodiazepine used primarily for sedation, anesthesia induction and maintenance, procedural sedation, and the treatment of acute seizures. It acts as a central nervous system depressant with sedative, anxiolytic (anti-anxiety), amnestic (impairing memory), muscle relaxant, hypnotic (sleep-inducing), and anticonvulsant properties. The drug works by enhancing the inhibitory action of gamma-aminobutyric acid (GABA) at GABA A receptors in the brain. This potentiation increases chloride ion influx into neurons leading to hyperpolarization and reduced neuronal excitability[1][3][5]. Midazolam is commonly administered intravenously or orally before medical procedures to induce relaxation or sleepiness and prevent memory formation of the event[7]. It is also used in intensive care settings for sedation of intubated patients and as an emergency treatment for status epilepticus[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on midazolam.